EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+64.5%
5Y CAGR+66.2%
Year-over-Year Change
Research and development spending
3Y CAGR
+64.5%/yr
vs +32.4%/yr prior
5Y CAGR
+66.2%/yr
Consistent
Acceleration
+32.2pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
12.7x
Strong expansion
Streak
6 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $221.04M | +66.3% |
| 2024 | $132.93M | +105.6% |
| 2023 | $64.66M | +30.3% |
| 2022 | $49.64M | +74.2% |
| 2021 | $28.50M | +63.6% |
| 2020 | $17.42M | +13.4% |
| 2019 | $15.37M | -5.0% |
| 2018 | $16.18M | +8.7% |
| 2017 | $14.88M | +3.5% |
| 2016 | $14.38M | - |